Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
Uni-Bio Science Group Ltd
0690Uni-Bio Science Group Limited, an investment holding company, researches and develops, manufactures, and sells biological and chemical pharmaceutical products to treat human diseases in the People's Republic of China. It operates in Chemical Pharmaceutical Products, Biological Pharmaceutical Products, and Pipeline Products. The company provides GeneTime, a prescription biological drug for wound healing; GeneSoft, a therapeutic drug for dry eye syndrome, corneal damage, and post-operative healing; Pinup, a voriconazole tablet to treat severe fungal infections; and Boshutai, a small molecule drug to treat diabetes. It is also developing prescription drugs, including rExendin-4 (Uni-E4) for Type 2 diabetes; and rhPTH 1-34 (Uni-PTH) for the treatment of osteoporosis in postmenopausal women, as well as Uni-GLP, a GLP-1 agent for the treatment of Type 2 diabetes. In addition, the company is involved in the distribution of hydrogel wound dressing for post-skin injury and minimally invasive surgery wound healing. Uni-Bio Science Group Limited was incorporated in 2001 and is headquartered in Sha Tin, Hong Kong. Address: No. 20 Science Park East Avenue, Sha Tin, Hong Kong
Analytics
Zielpreis von Wall Street
–KGV
3.6Dividendenrendite
–Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Schlüsselzahlen 0690
Dividenden-Analyse 0690
Dividendenwachstum über 5 Jahre
–Kontinuierliches Wachstum
–Ausschüttungsquote 5-Jahres-Durchschnitt
–Verlauf der Dividende 0690
Bewertung der Aktie 0690
Finanzen 0690
Ergebnisse | 2019 | Dynamik |